X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9129) 9129
Newsletter (49) 49
Magazine Article (20) 20
Book Chapter (10) 10
Newspaper Article (4) 4
Book Review (2) 2
Web Resource (2) 2
Conference Proceeding (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8947) 8947
rituximab (8145) 8145
female (4602) 4602
male (4521) 4521
antibodies, monoclonal, murine-derived (4381) 4381
middle aged (3730) 3730
antibodies, monoclonal - therapeutic use (3683) 3683
antibodies, monoclonal, murine-derived - therapeutic use (3264) 3264
adult (3102) 3102
aged (2890) 2890
treatment outcome (2770) 2770
antineoplastic combined chemotherapy protocols - therapeutic use (2566) 2566
hematology (2256) 2256
oncology (2228) 2228
antineoplastic agents - therapeutic use (1783) 1783
therapy (1580) 1580
immunologic factors - therapeutic use (1467) 1467
antibodies, monoclonal, murine-derived - administration & dosage (1349) 1349
antibodies, monoclonal - administration & dosage (1142) 1142
aged, 80 and over (1130) 1130
chemotherapy (1114) 1114
cyclophosphamide - administration & dosage (1112) 1112
lymphoma, large b-cell, diffuse - drug therapy (1102) 1102
non-hodgkins-lymphoma (1095) 1095
cyclophosphamide - therapeutic use (1081) 1081
prognosis (980) 980
immunosuppressive agents - therapeutic use (959) 959
lymphomas (928) 928
vincristine - administration & dosage (895) 895
retrospective studies (894) 894
cancer (889) 889
prednisone - therapeutic use (880) 880
rheumatology (853) 853
doxorubicin - administration & dosage (844) 844
remission induction (842) 842
care and treatment (836) 836
antineoplastic combined chemotherapy protocols - administration & dosage (807) 807
adolescent (798) 798
vincristine - therapeutic use (795) 795
animals (787) 787
young adult (783) 783
transplantation (775) 775
doxorubicin - therapeutic use (767) 767
antibodies, monoclonal, murine-derived - adverse effects (763) 763
prednisone - administration & dosage (763) 763
lymphoma (729) 729
recurrence (727) 727
antibodies, monoclonal - adverse effects (712) 712
cyclophosphamide (708) 708
anti-cd20 monoclonal-antibody (700) 700
immunology (694) 694
disease-free survival (679) 679
medicine & public health (665) 665
antirheumatic agents - therapeutic use (657) 657
lymphoma, b-cell - drug therapy (639) 639
follow-up studies (623) 623
antigens, cd20 - immunology (622) 622
abridged index medicus (611) 611
combined modality therapy (600) 600
b-lymphocytes - immunology (597) 597
immunotherapy (588) 588
drug therapy, combination (566) 566
drug therapy (555) 555
lymphoma, non-hodgkin - drug therapy (552) 552
efficacy (534) 534
disease (527) 527
antineoplastic combined chemotherapy protocols - adverse effects (513) 513
b-cell lymphoma (505) 505
lymphoma, large b-cell, diffuse - pathology (492) 492
survival (491) 491
lymphoma, follicular - drug therapy (482) 482
child (475) 475
time factors (474) 474
arthritis, rheumatoid - drug therapy (472) 472
medicine, general & internal (471) 471
trial (471) 471
mice (469) 469
antineoplastic agents (462) 462
monoclonal antibodies (438) 438
antibodies (432) 432
antimitotic agents (431) 431
risk factors (427) 427
clinical trials as topic (423) 423
leukemia, lymphocytic, chronic, b-cell - drug therapy (423) 423
b-lymphocytes - drug effects (422) 422
research (421) 421
drug administration schedule (418) 418
monoclonal-antibody (402) 402
survival analysis (398) 398
hemic and lymphatic diseases (396) 396
chronic lymphocytic-leukemia (395) 395
follicular lymphoma (391) 391
health aspects (391) 391
analysis (389) 389
neoplasm staging (387) 387
elderly-patients (382) 382
antineoplastic agents - administration & dosage (380) 380
rheumatoid arthritis (363) 363
antibodies, monoclonal, humanized (360) 360
expression (357) 357
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8537) 8537
Japanese (272) 272
French (161) 161
German (117) 117
Chinese (108) 108
Spanish (104) 104
Italian (28) 28
Russian (28) 28
Hungarian (22) 22
Polish (19) 19
Czech (15) 15
Danish (14) 14
Portuguese (14) 14
Croatian (10) 10
Dutch (8) 8
Finnish (6) 6
Hebrew (6) 6
Norwegian (5) 5
Korean (4) 4
Romanian (2) 2
Serbian (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 5, pp. 417 - 427
This study of ANCA-associated vasculitis compared a single course of rituximab with conventional immunosuppression with cyclophosphamide followed by... 
WEGENERS-GRANULOMATOSIS | MAINTENANCE | ANTIBODY-ASSOCIATED VASCULITIS | RENAL VASCULITIS | CYCLOPHOSPHAMIDE | RITUXIMAB | ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES | RANDOMIZED-TRIAL | SYSTEMIC VASCULITIDES | CELL-ACTIVATION | MEDICINE, GENERAL & INTERNAL | ACTIVATION | SPECIFICITY | PROTEINASE-3 | LYMPHOCYTES | Recurrence | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Double-Blind Method | Drug Administration Schedule | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | B-Lymphocytes | Rituximab | Cyclophosphamide - adverse effects | Remission Induction | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Cyclophosphamide - therapeutic use | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Drug Therapy, Combination | Antibodies, Monoclonal, Murine-Derived - adverse effects | Azathioprine - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Immunologic Factors - therapeutic use | Immunosuppression | Vasculitis | Drug therapy | Patient outcomes | Disease | Medical treatment | Hypersensitivity | Patients | Immunosuppressive agents | Cyclophosphamide | Infectious diseases | Lymphocytes B | Antineutrophil cytoplasmic antibodies | Remission | Azathioprine
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 196 - 206
... (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy seen in first-line treatment, we initiated a phase 2 trial to test whether the subsequent use of rituximab and CHOP would improve the outcome of patients with PTLD... 
Hematology, Oncology and Palliative Medicine | SOLID-ORGAN TRANSPLANTATION | VIRAL LOAD | THERAPY | MANAGEMENT | REDUCTION | ONCOLOGY | IMMUNOSUPPRESSION | DISEASE | LYMPHOMA | RISK | EPSTEIN-BARR-VIRUS | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Organ Transplantation - pathology | Cyclophosphamide - therapeutic use | Epstein-Barr Virus Infections - therapy | Vincristine - administration & dosage | Adult | Female | Herpesvirus 4, Human - pathogenicity | Prednisolone - therapeutic use | France | Lymphoproliferative Disorders - etiology | Doxorubicin - administration & dosage | Antigens, CD20 - immunology | Rituximab | Lymphoproliferative Disorders - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organ Transplantation - adverse effects | Adolescent | Vincristine - therapeutic use | Epstein-Barr Virus Infections - diagnosis | Lymphoproliferative Disorders - drug therapy | Aged | Germany | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Organ transplant recipients | Clinical trials | Product development | Epstein-Barr virus | Universities and colleges | Prednisolone | Cancer | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Lymphoproliferative Disorders | Antineoplastic Combined Chemotherapy Protocols | Organ Transplantation | Vincristine | Doxorubicin | Herpesvirus 4, Human | Life Sciences | Immunology | Epstein-Barr Virus Infections
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 6, pp. 520 - 531
...) combined with the anti-CD20 monoclonal antibody rituximab (e.g., R-CHOP). 2 – 4 Only a minority of patients have a complete remission, and relapse or progression usually occurs within 2 to 3 years, resulting in an overall survival of less than 5 years. To improve this grim prognosis, . . . 
SURVIVAL | FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | RITUXIMAB | COMBINATION | FLUDARABINE | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 424 - 435
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 11, pp. 997 - 1007
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1090 - 1099
...), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL... 
Hematology, Oncology and Palliative Medicine | B-CELL RECEPTOR | ONCOLOGY | CYCLOPHOSPHAMIDE | NK CELL | INITIAL THERAPY | PCI-32765 | OPEN-LABEL | QUALITY-OF-LIFE | TARGETING BTK | INHIBITOR | FLUDARABINE | Prognosis | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Neoplasm Recurrence, Local - mortality | Patient Selection | Dose-Response Relationship, Drug | Aged, 80 and over | Adult | Female | Pyrazoles - adverse effects | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Rituximab | Survival Rate | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Disease-Free Survival | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Antimitotic agents | Monoclonal antibodies | Safety and security measures | Antineoplastic agents
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 19, pp. 1771 - 1780
Journal Article